Concise Review: Cardiac Disease Modeling Using Induced Pluripotent Stem Cells

Stem Cells

Volumn 33, Issue 9, 2015, Pages 2643-2651

  Yang, Chunbo ^a   Al Aama, Jumana ^b   Stojkovic, Miodrag ^c   Keavney, Bernard ^d   Trafford, Andrew ^d   Lako, Majlinda ^a   Armstrong, Lyle ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c University of Kragujevac Medical Faculty   (Serbia)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiac; Differentiation; Embryonic stem cells; Induced pluripotent stem cells

Indexed keywords

POTASSIUM CHANNEL; SODIUM CHANNEL;

ARTICLE; CALCIUM CHANNELOPATHY; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CELL COMMUNICATION; CELL DIFFERENTIATION; CONGESTIVE CARDIOMYOPATHY; DISEASE MODEL; EMBRYONIC STEM CELL; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENETIC DISORDER; HEART DISEASE; HEART MUSCLE CELL; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; IN VITRO STUDY; LEOPARD SYNDROME; LONG QT SYNDROME; LOSS OF FUNCTION MUTATION; PLURIPOTENT STEM CELL; POTASSIUM CHANNELOPATHY; SIGNAL TRANSDUCTION; SODIUM CHANNELOPATHY; TIMOTHY SYNDROME; ANIMAL; CARDIAC MUSCLE CELL; CELL CULTURE; INDUCED PLURIPOTENT STEM CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALIA;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; HEART DISEASES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC;

EID: 84940467026     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2070     Document Type: Article

References (105)

1. van der Linde D, Konings EE, Slager MA, et al., Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 2241-2247.
2. Badorff C, Brandes RP, Popp R, et al., Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation 2003; 107: 1024-1032.
3. Gonzales C, Pedrazzini T,. Progenitor cell therapy for heart disease. Exp Cell Res 2009; 315: 3077-3085.
4. Beltrami AP, Barlucchi L, Torella D, et al., Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114: 763-776.
5. Perino MG, Yamanaka S, Li J, et al., Cardiomyogenic stem and progenitor cell plasticity and the dissection of cardiopoiesis. J Mol Cell Cardiol 2008; 45: 475-494.
6. Kehat I, Kenyagin-Karsenti D, Snir M, et al., Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001; 108: 407-414.
7. Mallon BS, Chenoweth JG, Johnson KR, et al., StemCellDB: The human pluripotent stem cell database at the National Institutes of Health. Stem Cell Res 2013; 10: 57-66.
8. Guenther MG, Frampton GM, Soldner F, et al., Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell 2010; 7: 249-257.
9. Mallon BS, Hamilton RS, Kozhich OA, et al., Comparison of the molecular profiles of human embryonic and induced pluripotent stem cells of isogenic origin. Stem Cell Res 2014; 12: 376-386.
10. Narazaki G, Uosaki H, Teranishi M, et al., Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 2008; 118: 498-506.
11. Zhang J, Wilson GF, Soerens AG, et al., Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009; 104: e30-41.
12. Stadtfeld M, Nagaya M, Utikal J, et al., Induced pluripotent stem cells generated without viral integration. Science 2008; 322: 945-949.
13. Okita K, Nakagawa M, Hyenjong H, et al., Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322: 949-953.
14. Kaji K, Norrby K, Paca A, et al., Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458: 771-775.
15. Fusaki N, Ban H, Nishiyama A, et al., Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85: 348-362.
16. Jia F, Wilson KD, Sun N, et al., A nonviral minicircle vector for deriving human iPSC cells. Nat Methods 2010; 7: 197-199.
17. Yu J, Hu K, Smuga-Otto K, et al., Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009; 324: 797-801.
18. Zhou H, Wu S, Joo JY, et al., Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4: 381-384.
19. Kim D, Kim CH, Moon JI, et al., Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4: 472-476.
20. Warren L, Manos PD, Ahfeldt T, et al., Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7: 618-630.
21. Laflamme MA, Gold J, Xu C, et al., Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol 2005; 167: 663-671.
22. Kehat I, Gepstein A, Spira A, et al., High-resolution electrophysiological assessment of human embryonic stem cell-derived cardiomyocytes: A novel in vitro model for the study of conduction. Circ Res 2002; 91: 659-661.
23. Xue T, Cho HC, Akar FG, et al., Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: Insights into the development of cell-based pacemakers. Circulation 2005; 111: 11-20.
24. Passier R, Oostwaard DW, Snapper J, et al., Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. Stem Cells 2005; 23: 772-780.
25. Xu XQ, Graichen R, Soo SY, et al., Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. Differentiation 2008; 76: 958-970.
26. Freund C, Ward-van Oostwaard D, Monshouwer-Kloots J, et al., Insulin redirects differentiation from cardiogenic mesoderm and endoderm to neuroectoderm in differentiating human embryonic stem cells. Stem Cells 2008; 26: 724-733.
27. Graichen R, Xu X, Braam SR, et al., Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentiation 2008; 76: 357-370.
28. Mummery C, Ward-van Oostwaard D, Doevendans P, et al., Differentiation of human embryonic stem cells to cardiomyocytes: Role of coculture with visceral endoderm-like cells. Circulation 2003; 107: 2733-2740.
29. Kattman SJ, Witty AD, Gagliardi M, et al., Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 2011; 8: 228-240.
30. Laflamme MA, Chen KY, Naumova AV, et al., Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007; 25: 1015-1024.
31. Yang L, Soonpaa MH, Adler ED, et al., Human cardiovascular progenitor cells develop from a KDR + embryonic-stem-cell-derived population. Nature 2008; 453: 524-528.
32. Pesl M, Acimovic I, Pribyl J, et al., Forced aggregation and defined factors allow highly uniform-sized embryoid bodies and functional cardiomyocytes from human embryonic and induced pluripotent stem cells. Heart Vessels 2014; 29: 834-846.
33. Olson EN,. Development. The path to the heart and the road not taken. Science 2001; 291: 2327-2328.
34. Mummery CL, Zhang J, Ng ES, et al., Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: A methods overview. Circ Res 2012; 111: 344-358.
35. David R, Stieber J, Fischer E, et al., Forward programming of pluripotent stem cells towards distinct cardiovascular cell types. Cardiovasc Res 2009; 84: 263-272.
36. Ma J, Guo L, Fiene SJ, et al., High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 2011; 301: H2006-2017.
37. Davis RP, Casini S, van den Berg CW, et al., Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 2012; 125: 3079-3091.
38. Zhang J, Wilson GF, Soerens AG, et al., Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009; 27: e30-41.
39. Moretti A, Bellin M, Welling A, et al., Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010; 363: 1397-1409.
40. Lahti AL, Kujala VJ, Chapman H, et al., Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 2012; 5: 220-230.
41. Itzhaki I, Maizels L, Huber I, et al., Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011; 471: 225-229.
42. Meijer van Putten RM, Mengarelli I, Guan K, et al., Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: A dynamic clamp study with virtual IK1. Front Physiol 2015; 6: 7.
43. Nerbonne JM, Kass RS,. Molecular physiology of cardiac repolarization. Physiol Rev 2005; 85: 1205-1253.
44. Hoekstra M, Mummery CL, Wilde AA, et al., Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front Physiol 2012; 3: 346.
45. Cordeiro JM, Nesterenko VV, Sicouri S, et al., Identification and characterization of a transient outward K + current in human induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol 2013; 60: 36-46.
46. Lieu DK, Fu JD, Chiamvimonvat N, et al., Mechanism-based facilitated maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Arrhythm Electrophysiol 2013; 6: 191-201.
47. Bett GC, Kaplan AD, Lis A, et al., Electronic "expression" of the inward rectifier in cardiocytes derived from human-induced pluripotent stem cells. Heart Rhythm 2013; 10: 1903-1910.
48. Trafford AW, Diaz ME, Negretti N, et al., Enhanced Ca2 + current and decreased Ca2 + efflux restore sarcoplasmic reticulum Ca2 + content after depletion. Circ Res 1997; 81: 477-484.
49. Walden AP, Dibb KM, Trafford AW,. Differences in intracellular calcium homeostasis between atrial and ventricular myocytes. J Mol Cell Cardiol 2009; 46: 463-473.
50. Xi J, Khalil M, Shishechian N, et al., Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. FASEB J 2010; 24: 2739-2751.
51. Pesl M, Acimovic I, Pribyl J, et al., Forced aggregation and defined factors allow highly uniform-sized embryoid bodies and functional cardiomyocytes from human embryonic and induced pluripotent stem cells. Heart Vessels 2014; 29: 834-846.
52. Weng Z, Kong CW, Ren L, et al., A simple, cost-effective but highly efficient system for deriving ventricular cardiomyocytes from human pluripotent stem cells. Stem Cells Dev 2014; 23: 1704-1716.
53. Zhang GQ, Wei H, Lu J, et al., Identification and characterization of calcium sparks in cardiomyocytes derived from human induced pluripotent stem cells. PLoS One 2013; 8: e55266.
54. Rao C, Prodromakis T, Kolker L, Chaudhry UA, Trantidou T, Sridhar A, Weekes C, Camelliti P, Harding SE, Darzi A, Yacoub MH, Athanasiou T, Terracciano CM,. The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells. Biomaterials 2013; 34: 2399-2411.
55. Rao C, Prodromakis T, Kolker L, et al., The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells. Biomaterials 2013; 34: 2399-2411.
56. Yu T, Miyagawa S, Miki K, et al., In vivo differentiation of induced pluripotent stem cell-derived cardiomyocytes. Circ J 2013; 77: 1297-1306.
57. Lundy SD, Zhu WZ, Regnier M, et al., Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev 2013; 22: 1991-2002.
58. Yang X, Rodriguez M, Pabon L, et al., Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol 2014; 72: 296-304.
59. Arshi A, Nakashima Y, Nakano H, et al., Rigid microenvironments promote cardiac differentiation of mouse and human embryonic stem cells. Sci Technol Adv Mater 2013; 14: 025003.
60. Bedada FB, Chan SS, Metzger SK, et al., Acquisition of a quantitative, stoichiometrically conserved ratiometric marker of maturation status in stem cell-derived cardiac myocytes. Stem Cell Reports 2014; 3: 594-605.
61. Ye L, Chang YH, Xiong Q, Zhang P, Zhang L, Somasundaram P, Lepley M, Swingen C, Su L, Wendel JS, Guo J, Jang A, Rosenbush D, Greder L, Dutton JR, Zhang J, Kamp TJ, Kaufman DS, Ge Y, Zhang J,. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell 2014; 15: 750-761.
62. Ye L, Chang YH, Xiong Q, et al., Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell 2014; 15: 750-761.
63. Müller M, Seufferlein T, Illing A, et al., Modelling human channelopathies using induced pluripotent stem cells: A comprehensive review. Stem Cells Int 2013; 2013: 496501.
64. Moss AJ, Schwartz PJ, Crampton RS, et al., The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991; 84: 1136-1144.
65. Hedley PL, Jorgensen P, Schlamowitz S, et al., The genetic basis of long QT and short QT syndromes: A mutation update. Hum Mutat 2009; 30: 1486-1511.
66. Wilde AA, Bezzina CR,. Genetics of cardiac arrhythmias. Heart 2005; 91: 1352-1358.
67. Matsa E, Rajamohan D, Dick E, et al., Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 2011; 32: 952-962.
68. Spencer CI, Baba S, Nakamura K, et al., Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia. Stem Cell Reports 2014; 3: 269-281.
69. Davis RP, Casini S, van den Berg CW, et al., Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 2012; 125: 3079-3091.
70. Fatima A, Kaifeng S, Dittmann S, et al., The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients. PLoS One 2013; 8: e83005.
71. Splawski I, Timothy KW, Sharpe LM, et al., Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119: 19-31.
72. Yazawa M, Hsueh B, Jia X, et al., Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011; 471: 230-234.
73. Fatima A, Xu G, Shao K, et al., In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem 2011; 28: 579-592.
74. Peters S, Trummel M, Meyners W,. Prevalence of right ventricular dysplasia-cardiomyopathy in a non-referral hospital. Int J Cardiol 2004; 97: 499-501.
75. Corrado D, Thiene G,. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: Clinical impact of molecular genetic studies. Circulation 2006; 113: 1634-1637.
76. Marcus FI, Zareba W, Calkins H, et al., Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: Results from the North American Multidisciplinary Study. Heart Rhythm 2009; 6: 984-992.
77. Hulot JS, Jouven X, Empana JP, et al., Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 2004; 110: 1879-1884.
78. Dalal D, Nasir K, Bomma C, et al., Arrhythmogenic right ventricular dysplasia: A United States experience. Circulation 2005; 112: 3823-3832.
79. Ackerman MJ, Priori SG, Willems S, et al., HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 2011; 13: 1077-1109.
80. Sen-Chowdhry S, Syrris P, Ward D, et al., Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007; 115: 1710-1720.
81. den Haan AD, Tan BY, Zikusoka MN, et al., Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet 2009; 2: 428-435.
82. Sen-Chowdhry S, Syrris P, Pantazis A, et al., Mutational heterogeneity, modifier genes, and environmental influences contribute to phenotypic diversity of arrhythmogenic cardiomyopathy. Circ Cardiovasc Genet 2010; 3: 323-330.
83. Xu T, Yang Z, Vatta M, et al., Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2010; 55: 587-597.
84. Asimaki A, Tandri H, Huang H, et al., A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2009; 360: 1075-1084.
85. Garcia-Gras E, Lombardi R, Giocondo MJ, et al., Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2006; 116: 2012-2021.
86. Basso C, Ronco F, Marcus F, et al., Quantitative assessment of endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy/dysplasia: An in vitro validation of diagnostic criteria. Eur Heart J 2008; 29: 2760-2771.
87. Ai D, Fu X, Wang J, et al., Canonical Wnt signaling functions in second heart field to promote right ventricular growth. Proc Natl Acad Sci USA 2007; 104: 9319-9324.
88. Ma D, Wei H, Lu J, et al., Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2013; 34: 1122-1133.
89. Caspi O, Huber I, Gepstein A, et al., Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet 2013; 6: 557-568.
90. Kim C, Wong J, Wen J, et al., Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 2013; 494: 105-110.
91. Carvajal-Vergara X, Sevilla A, D'Souza SL, et al., Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010; 465: 808-812.
92. Molkentin JD,. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 2004; 63: 467-475.
93. Willott RH, Gomes AV, Chang AN, et al., Mutations in troponin that cause HCARDIOYMYOCYTE, DCARDIOYMYOCYTE AND RCARDIOYMYOCYTE: What can we learn about thin filament function? J Mol Cell Cardiol 2010; 48: 882-892.
94. Sun N, Yazawa M, Liu J, et al., Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 2012; 4: 130ra147.
95. Hajjar RJ, Zsebo K, Deckelbaum L, et al., Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008; 14: 355-367.
96. Engelmeier RS, O'Connell JB, Walsh R, et al., Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial. Circulation 1985; 72: 536-546.
97. Pellikka PA, McCully RB,. Stress echocardiography: So much to do, so little time. J Am Coll Cardiol 2007; 50: 1990-1991.
98. Reamon-Buettner SM, Ciribilli Y, Inga A, et al., A loss-of-function mutation in the binding domain of HAND1 predicts hypoplasia of the human hearts. Hum Mol Genet 2008; 17: 1397-1405.
99. Hinton RB, Martin LJ, Rame-Gowda S, et al., Hypoplastic left heart syndrome links to chromosomes 10q and 6q and is genetically related to bicuspid aortic valve. J Am Coll Cardiol 2009; 53: 1065-1071.
100. Iascone M, Ciccone R, Galletti L, et al., Identification of de novo mutations and rare variants in hypoplastic left heart syndrome. Clin Genet 2012; 81: 542-554.
101. Jiang Y, Habibollah S, Tilgner K, et al., An induced pluripotent stem cell model of hypoplastic left heart syndrome (HLHS) reveals multiple expression and functional differences in HLHS-derived cardiomyocytes. Stem Cells Transl Med 2014; 3: 416-423.
102. Maron BJ, Gardin JM, Flack JM, et al., Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92: 785-789.
103. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al., A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation. Cell 1990; 62: 999-1006.
104. Seidman JG, Seidman C,. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell 2001; 104: 557-567.
105. Lan F, Lee AS, Liang P, et al., Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013; 12: 101-113.